EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis

Wirksamkeit und Sicherheit oxaliplatinbasierter Chemotherapie als Erstlinientherapie bei älteren Patient:innen mit metastasiertem kolorektalem Karzinom: Metaanalyse

Shaoqing Fan, Zeming Zhao, Haiqian Wang, Handong Wang, Wenbo Niu

Frontiers in Oncology · 07.04.2025 · 15

DOI: 10.3389/fonc.2025.1567732 ↗

Auf einen Blick

Sieben RCTs mit 1.839 Patient:innen zeigen unter Oxaliplatin bessere Tumoransprechen als unter Nicht-Oxaliplatin-Regimen. Ein Überlebensvorteil war nicht signifikant.

Fragestellung

Verbessert oxaliplatinbasierte Chemotherapie in der Erstlinie bei älteren Patient:innen mit metastasiertem kolorektalem Karzinom Wirksamkeit und Sicherheit gegenüber Nicht-Oxaliplatin-Regimen?

Methode

Metaanalyse von RCTs; Suche in PubMed, Web of Science, Cochrane Library und chinesischen Datenbanken bis November 2024; Analyse mit Fixed- oder Random-Effects-Modellen in STATA 14.0.

Ergebnisse

ORR: OR 2,18 (95 %-KI 1,75–2,72); CR: OR 2,57 (1,11–5,97); PR: OR 1,69 (1,28–2,22). OS: HR 0,97 (0,86–1,08); PFS: HR 0,90 (0,79–1,01). Mehr Neutropenie, Diarrhö und sensorische Neuropathie.

Einschränkungen

DCR-Heterogenität (I²=66 %) durch Regimeunterschiede; Sicherheitsprofil und Heterogenität in Subgruppen unterschiedlich.

Schlussfolgerung der Autor:innen

Oxaliplatinbasierte Erstlinientherapie verbesserte bei älteren mCRC-Patient:innen das Tumoransprechen, ohne klare Überlebensvorteile zu zeigen. Die Therapieentscheidungen sollten Nutzen und Toxizität abwägen.

Kernaussagen

  • Bessere Tumoransprechen unter Oxaliplatin
  • Kein signifikanter Vorteil für OS oder PFS
  • Mehr Grad-3/4-Neutropenie, Diarrhö und Neuropathie

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 07.04.2025. Verfasst von Shaoqing Fan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The global burden of colorectal cancer (CRC) continues to rise, with elderly populations disproportionately affected. Despite oxaliplatin’s established role in first-line metastatic CRC (mCRC) therapy, its clinical utility in older adults remains debated due to concerns over efficacy, toxicity, and survival outcomes. This meta-analysis evaluates the therapeutic benefits and risks of oxaliplatin-based regimens in elderly patients with mCRC, with emphasis on tumor response, survival endpoints, and treatment-related toxicities.

Methods

We systematically reviewed PubMed, Web of Science, Cochrane Library, and Chinese databases (CNKI, Wan Fang) through November 2024 for randomized controlled trials (RCTs) comparing oxaliplatin-based chemotherapy to non-oxaliplatin regimens in patients aged ≥65 with mCRC. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), complete response (CR), partial response (PR), disease control rate (DCR), and grade 3–4 adverse events. Data were pooled using random- or fixed-effects models in STATA 14.0 based on heterogeneity (I² statistic). Subgroup analyses explored heterogeneity sources, including chemotherapy combinations (e.g., bevacizumab, panitumumab).

Results

Seven RCTs (1,839 patients) met inclusion criteria. Oxaliplatin significantly improved tumor response rates versus control regimens: ORR (OR 2.18, 95% CI 1.75–2.72; P <0.001), CR (OR 2.57, 1.11–5.97; P =0.028), and PR (OR 1.69, 1.28–2.22; P <0.001). No significant survival benefit was observed for OS (HR 0.97, 0.86–1.08; P =0.58) or PFS (HR 0.90, 0.79–1.01; P =0.07), though trends favored oxaliplatin. Grade 3–4 neutropenia (RR 1.84, 1.32–2.57), diarrhea (RR 2.01, 1.45–2.78), and sensory neuropathy (RR 3.12, 1.98–4.91) were more frequent with oxaliplatin. Subgroup analysis attributed DCR heterogeneity (I²=66%) to regimen differences, with reduced variability in bevacizumab/pantiumumab-combined subgroups.

Discussion

This analysis demonstrates oxaliplatin’s capacity to enhance tumor response in elderly mCRC patients, potentially alleviating symptoms and improving quality of life. However, the absence of significant survival gains underscores the complex interplay between tumor biology and therapeutic resistance. Mechanistically, chemotherapy-driven clonal selection may favor residual resistant subpopulations, as evidenced by liquid biopsy studies linking tumor evolution to disease progression. While toxicity profiles were manageable, the elevated risk of neurotoxicity and myelosuppression necessitates vigilant monitoring in this vulnerable cohort.

Conclusion

Oxaliplatin-based first-line therapy provides clinically meaningful tumor response improvements in elderly mCRC patients, though survival advantages remain elusive. Treatment decisions should balance response benefits against toxicity risks, prioritizing individualized strategies informed by geriatric assessments and molecular profiling. Future trials must integrate biomarker-driven approaches (e.g., ctDNA monitoring, RAS/RAF stratification) to optimize therapeutic precision in aging populations.

Schlagwörter

Stichwörter der Autor:innen

elderlyfirst-line treatmentmeta-analysismetastatic colorectal canceroxaliplatin

Autor:innen und Institutionen

  • Department of General Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Nursing, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Zitieren

APA

Fan, S., Zhao, Z., Wang, H., Wang, H., & Niu, W. (2025). Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1567732

Vancouver

Fan S, Zhao Z, Wang H, Wang H, Niu W. Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1567732

BibTeX
@article{Fan2025,
  author = {Fan, Shaoqing and Zhao, Zeming and Wang, Haiqian and Wang, Handong and Niu, Wenbo},
  title = {Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1567732}
}
Kostenlos starten →